Aktienanalyse zu Strata Skin Sciences Inc (SSKN)SSKNStrata Skin Sciences Inc

STRATA Skin Sciences, Inc. is a medical technology company in dermatology. The Company is engaged in developing, commercializing and marketing products for the treatment of dermatologic conditions. The Company operates through two segments: Dermatology Recurring Procedures and Dermatology Procedures Equipment. The Company’s products include the XTRAC and Pharos excimer lasers and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its products also include the TheraClear Acne Therapy System utilized in the treatment of mild to moderate inflammatory, comedonal and pustular acne. The XTRAC and Pharos excimer laser technology emits highly concentrated ultraviolet (UV) light targeted primarily towards autoimmune dermatological skin disorders, such as psoriasis, vitiligo, atopic dermatitis, and eczema, among others. VTRAC is a UV light lamp system that works in much the same way as the XTRAC. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Strata Skin Sciences Inc (SSKN) is not a good buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The company is facing significant financial challenges, including a recent deregistration filing with the SEC, poor financial performance, and bearish technical indicators. Additionally, there are no positive trading signals or catalysts to suggest a turnaround in the near term.

1 analysts cover SSKN: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 4.00.